Does Dr. EDUARDO GONZALEZ-STUBBE have financial conflicts of interest?

Dr. EDUARDO GONZALEZ-STUBBE (M.D.) has received a total of $1,305 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,305 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. EDUARDO GONZALEZ-STUBBE?

According to CMS Open Payments data, Dr. EDUARDO GONZALEZ-STUBBE received funding from GENENTECH USA ($312), REGENERON PHARMACEUTICALS ($268), and REGENERON HEALTHCARE SOLUTIONS ($240).

Does Dr. EDUARDO GONZALEZ-STUBBE receive research grants or speaking fees?

Dr. EDUARDO GONZALEZ-STUBBE has received $1,305 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. EDUARDO GONZALEZ-STUBBE

M.D.Real-Time Hydrated

Specialty: Ophthalmology

Practice Location: NEW ORLEANS, LA 70115

NPI Number: 1245508183

LIFETIME INDUSTRY VALUE

$1,305

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GONZALEZ-STUBBE is a verified Ophthalmology practitioner based in NEW ORLEANS, LA.

Between 2021 and 2025, Dr. GONZALEZ-STUBBE had an overall industry promotional and research financial footprint of $1,305 as recorded in the federal CMS Open Payments database.

$1,305 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. GONZALEZ-STUBBE's primary funding source is GENENTECH USA, which accounts for $312 (representing 23.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENENTECH USA

Rank 1

$312

23.9%

REGENERON PHARMACEUTICALS

Rank 2

$268

20.5%

REGENERON HEALTHCARE SOLUTIONS

Rank 3

$240

18.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.